

ELISPOT technology - tricks and triumphs

9th July 2004

Agenda

Morning

- 9:30 - 10:00 **Registration – Tea, coffee and biscuits**
- 10:00 - 10:10 **Introduction by the Co - Chair.** *Dr Colin M. Dayan, University of Bristol*
- 10:10 -10:50 **ELISPOT: the past, the present and the future.**
Prof. Dr. Paul V. Lehmann, Western Reserve University. Founder, Owner and President of CTL.
- 10:50 – 11:10 **Monitoring Immune Function** *Dr Mark Bradford BDB Biosciences*
- 11:10 -11:30 **Morning coffee/tea break in the exhibition hall**
- 11:30 - 11:50 **Multiscreen Plate Selection for Optimum ELISPOT**
Heather Glazebrook, Millipore UK
- 11:50 – 12:10 **Automated platforms for cell counts viabilities and apoptosis assessments**
Dr. Kevin McCormack, Guava Technologies
- 12:10 – 12:30 **Troubleshooting the Elispot Assay**
Sylvia Janetzki, Zellnet Consulting Inc
- 12:30 - 1:30 **Lunch and meet the companies**
- Afternoon**
- 1:30 - 1:50 **Introduction to afternoon session by the Co - Chair.**
Dr Mark Peakman, Guy's Hospital
- 1:50 - 2:10 **ELISPOT assays as a useful and sensitive tool for monitoring T cell responses** *Marleen Simmelink, U-Cytech Biosciences*
- 2:10 - 2:30 **Dual-color ELISPOT by enzymatic and fluorescence detection** *Dr John Wijdenes - CEO, Diaclone*
- 2:30 - 2:50 **21 CFR Part 11 requirements for ELISPOT Technology** *Johannes Albrecht, CTL-Europe*
- 2:50 - 3:10 **Afternoon Tea/Coffee and cakes with the companies**
- 3:10 - 3:30 **The Granzyme B ELISPOT assay: an alternative for monitoring cell-mediated cytotoxicity.**
John Voorn, Sanquin reagents
- 3:30 - 3:50 **ELISPOT in routine diagnosis.** *Dr. Reinhold Werner-Meier, Autoimmun Diagnostika*
- 3:50 - 4:10 **Optimization of ELISPOT for detection of Th2 cytokines in allergy,** *Niklas Ahlborg, Mabtech AB*
- 4:10 – 4:30 **Statistical analysis of ELISPOT data: significance thresholds and number of replicate wells**
Dr Alexey Karulin , CTL-Europe
- 4:30 **Close**